Anti-PDL1 Immunotherapy Demonstrates Efficacy in Phase 2 NSCLC StudyLea EslavaKimPharmD
The immunosuppressive microenvironment of solid tumours reduces the antitumour activity of chimeric antigen receptor T cells (CAR-T cells). Here, we show that the release—through the implantation of a hyaluronic acid hydrogel—of CAR-T cells targeting t
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysis. The pooled hazard ratio (HR) was used to analyze the overall survival (OS), progression-free survival (PFS), and the pooled relative...
Conclusion: In the treatment of solid tumors, PD1/PDL1 inhibitors combined with RT and anti-angiogenic drugs achieved a positive response and better survival benefits than monotherapy or dual therapy. In addition, combination therapy is tolerable and safe. Registration: PROSPERO ID: CRD42022371433. ...
These toxicities are a reminder of potential novel toxicities related to new drugs and highlight the need for a multidisciplinary approach to recognize and treat such adverse...doi:10.1016/j.jtho.2017.09.716Morán, T.Vila, L.Teruel, I.
Efficacy and safety of PD1/PDL1 inhibitors combined with radiotherapy and antiangiogenic drugs for hepatocellular carcinoma: a systematic review and meta-analysisXIAN, F.WU, J.YUAN, Y.-L.BIE, J.XU, G.-H.European Review for Medical & Pharmacological Sciences...